<DOC>
	<DOC>NCT02006290</DOC>
	<brief_summary>The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be evaluated.</brief_summary>
	<brief_title>Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Male or female subjects with a diagnosis of idiopathic Parkinson's disease. Daily Ldopa dose between 300 and 1200 mg. MBRS score &gt;1. Surgical intervention for Parkinson's disease. History of troublesome dyskinesias. Any significant AXIS I psychiatric disease.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>